Hologic, Inc. (NASDAQ:HOLX) Short Interest Down 25.0% in February

Hologic, Inc. (NASDAQ:HOLX) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 4,440,000 shares, a decrease of 25.0% from the February 13th total of 5,920,000 shares. Approximately 2.0% of the shares of the stock are short sold. Based on an average trading volume of 2,420,000 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Trading of Hologic

Institutional investors have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Brooklyn Investment Group raised its position in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 145 shares in the last quarter. Empirical Finance LLC lifted its stake in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Trivant Custom Portfolio Group LLC grew its stake in Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 169 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 1.8 %

NASDAQ HOLX opened at $61.82 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a fifty-two week low of $59.55 and a fifty-two week high of $84.67. The stock has a market capitalization of $13.87 billion, a PE ratio of 19.50, a PEG ratio of 2.14 and a beta of 0.97. The business has a fifty day moving average price of $66.94 and a two-hundred day moving average price of $74.51.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on HOLX. Evercore ISI lowered their price objective on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Stephens reiterated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.